

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/JP2018/033143

**A. CLASSIFICATION OF SUBJECT MATTER**

Int.Cl. A61K38/46(2006.01) i, A61K9/08(2006.01) i, A61K47/02(2006.01) i,  
 A61K47/10(2006.01) i, A61K47/26(2006.01) i, A61K47/68(2017.01) i,  
 A61P25/00(2006.01) i, C07K16/28(2006.01) i, C07K19/00(2006.01) i,  
 C12N9/14(2006.01) i, C12N15/62(2006.01) i

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl. A61K38/46, A61K9/08, A61K47/02, A61K47/10, A61K47/26, A61K47/68, A61P25/00,  
 C07K16/28, C07K19/00, C12N9/14, C12N15/62

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Published examined utility model applications of Japan	1922-1996
Published unexamined utility model applications of Japan	1971-2018
Registered utility model specifications of Japan	1996-2018
Published registered utility model applications of Japan	1994-2018

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

JSTPlus/JMEDPlus/JST7580 (JDreamIII), CAPLUS/MEDLINE/EMBASE/BIOSIS (STN)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2016/208695 A1 (JCR PHARMACEUTICALS CO., LTD.) 29 December 2016, claims, paragraphs [0199]- [0200], examples, etc. & US 2018/0171012 A1, claims, paragraphs [0631]-[0632], examples & EP 3315606 A1	1-29

Further documents are listed in the continuation of Box C.

See patent family annex.

- |   |  |
|---|--|
| * Special categories of cited documents:  | "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "A" document defining the general state of the art which is not considered to be of particular relevance  | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "E" earlier application or patent but published on or after the international filing date   | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family  |
| "O" document referring to an oral disclosure, use, exhibition or other means  |  |
| "P" document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search  
 29 October 2018 (29.10.2018)

Date of mailing of the international search report  
 13 November 2018 (13.11.2018)

Name and mailing address of the ISA/  
 Japan Patent Office  
 3-4-3, Kasumigaseki, Chiyoda-ku,  
 Tokyo 100-8915, Japan

Authorized officer  
  
 Telephone No.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2018/033143

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP 2017-519009 A (SANTA MARIA BIOTHERAPEUTICS, INC.) 13 July 2017, claims, paragraphs [0091], [0099], examples, etc. & WO 2015/192127 A2, claims, paragraphs [0099], [0107], examples & US 2017/0202909 A1 & EP 3155008 A2	1-29
Y	JP 2016-502528 A (ALTEOGEN INC.) 28 January 2016, claims, paragraphs [0027]-[0029], examples, etc. & US 2015/0313996 A1, claims, paragraphs [0039]-[0041], examples & WO 2014/084508 A1 & EP 2926834 A1	1-29
Y	JP 2013-534526 A (SHIRE HUMAN GENETIC THERAPIES, INC.) 05 September 2013, claims, paragraphs [0110]-[0116], examples, etc. & WO 2011/163648 A1, claims, paragraphs [0303]-[0308], examples & US 2012/0003202 A1 & EP 2588130 A1	1-29
Y	添付文書, エラプレース (登録商標) 点滴静注液 6mg, July 2016, entire text, non-official translation (attached document, ELAPRASE (registered trademark) intravenous drip infusion 6 mg)	1-29
Y	添付文書, アクテムラ (登録商標) 点滴静注用 80mg/アクテムラ (登録商標) 点滴静注用 200mg/アクテムラ (登録商標) 点滴静注用 400mg, November 2016, entire text, non-official translation (attached document, ACTEMRA (registered trademark) intravenous drip infusion 80 mg)/ACTEMRA (registered trademark) intravenous drip infusion 200 mg)/ACTEMRA (registered trademark) intravenous drip infusion 400 mg)	1-29
P, X	WO 2018/124277 A1 (JCR PHARMACEUTICALS CO., LTD.) 05 July 2018, claims, examples, etc. (Family: none)	1-29